Matrix metalloproteinase 2; Matrix metalloproteinase 9 (MMP-2; MMP-9)

Matrix metalloproteinase 2 (MMP-2, gelatinase A, 72 kDa) and matrix metalloproteinase 9 (MMP-9, gelatinase B, 92 kDa) are multidomain zinc-dependent endopeptidases central to the regulated breakdown of the extracellular matrix under both physiological and pathological conditions. Their canonical structure includes an N-terminal pro-domain, a catalytic domain with fibronectin-like inserts, and a C-terminal hemopexin-like domain. They are secreted as inactive zymogens (proMMP-2, proMMP-9) and activated by proteolytic cleavage via upstream proteases (e.g., MMP-3, plasmin). MMP-2 and MMP-9 are tightly regulated by tissue inhibitors of metalloproteinases (TIMPs): MMP-2 complexes with TIMP-2; MMP-9 with TIMP-1. Both act on multiple ECM components (collagen types IV, I, III, V, laminin, elastin) and regulate the bioavailability and activity of cytokines, chemokines, and growth factors—thereby influencing inflammatory responses, tissue repair, angiogenesis, cell proliferation, migration, and apoptosis. Dysregulation of either leads to disease progression, most notably in cancer (where they promote metastasis), cardiovascular and neurodegenerative diseases (e.g., by mediating blood-brain barrier disruption), and inflammatory conditions. Thus, they are prominent pharmacological targets, but therapeutic selectivity and safety remain challenging due to shared domains and similar substrate profiles. Drug development has focused on small-molecule inhibitors, with only a few approved agents; others remain experimental due to limited selectivity and adverse effects. Measuring circulating MMP-2 and MMP-9 serves as a useful biomarker for disease diagnosis and prognosis. Inhibitor strategies must consider their dual roles in pathology and normal physiology, particularly regarding tissue repair and immune modulation.

Other names

gelatinase A72 kDa type IV collagenasegelatinase B92 kDa type IV collagenase92 kDa gelatinase

Inhibition of MMP enzymatic activity (by chelating the active site zinc or binding to the catalytic domain); Inhibition of activation cascade (blocking conversion from proenzyme to active enzyme); Interference with substrate binding